ReviewFrontiers in allergy2026
Tic disorders and allergic diseases: mechanistic links and the impact of allergy management - a narrative review.
Review in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tic disorders are childhood-onset neuropsychiatric conditions that frequently co-occur with allergic diseases, including asthma, allergic rhinitis, and atopic dermatitis. This narrative review maps the current clinical and mechanistic evidence linking allergic conditions to tic disorders and evaluates whether allergy focused interventions may modify tic severity. Across multiple epidemiological studies, allergic diseases are reported more often in children with tic disorders than in controls. However, direct clinical evidence supporting a canonical "central allergic response" within the brain (e.g., IgE-driven allergic effector mechanisms in the CNS) in primary tic disorders remains limited. The available literature instead more strongly supports indirect, peripheral, brain directed pathways. Peripheral inflammatory mediators may modulate the neurovascular unit and glial reactivity, thereby influencing cortico-striato-thalamo-cortical circuit excitability. Histamine, acting as both an immune mediator and a neuromodulator, may further intersect with dopaminergic signalling relevant to tic expression. In parallel, allergy related symptom burden, particularly sleep disruption and psychological stress, may contribute to tic exacerbation. Observational studies suggest that controlling allergic symptoms can be associated with reduced tic severity in some individuals, although certain anti allergic agents have been reported to coincide with tic worsening in selected cases. Overall, current findings support a model in which allergic conditions influence tic disorders primarily via immune signalling and symptom burden rather than through a direct central allergic mechanism. Allergy assessment and management may be considered in selected patients, but mechanistic studies and controlled trials are needed to clarify causality and guide evidence-based care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.